×
About 69,488 results

ALLMedicine™ Melanoma Center

Research & Reviews  23,189 results

Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson's Disease.
https://doi.org/10.1002/ana.26410
Annals of Neurology; Shen J, Amari N et. al.

May 21st, 2022 - Using a multi-cohort, Discovery-Replication-Validation design, we sought new plasma biomarkers that predict which PD individuals will experience cognitive decline. In 108 Discovery Cohort PD individuals and 83 Replication Cohort PD individuals, we...

5‑Aza‑dC suppresses melanoma progression by inhibiting GAS5 hypermethylation.
https://doi.org/10.3892/or.2022.8334
Oncology Reports; Zhang YJ, Xie R et. al.

May 21st, 2022 - The in‑depth study of melanoma pathogenesis has revealed that epigenetic modifications, particularly DNA methylation, is a universal inherent feature of the development and progression of melanoma. In the present study, the analysis of the tumor s...

Diagnostic impact of 18F-FDG PET/CT imaging on the detection of immune-related adverse ...
https://doi.org/10.1007/s12094-022-02840-9 10.1016/j.canlet.2015.10.009 10.1038/nrclinonc.2014.174 10.4103/apjon.apjon_4_17 10.1186/s41747-020-00190-1 10.1007/s12094-020-02397-5 10.1007/s00259-017-3870-6 10.1016/j.cell.2020.03.001 10.1097/RLU.0000000000002453 10.1053/j.semnuclmed.2020.06.001 10.3389/fphar.2017.00730 10.1093/cid/ciy1025 10.3390/cancers13194928 10.1093/annonc/mdx286 10.1007/s00261-019-01935-2 10.1259/bjr.20200663 10.2217/imt-2018-0146 10.2217/imt-2019-0077 10.1093/annonc/mdx403 10.1158/2326-6066.CIR-15-0102 10.1038/s41379-018-0013-y 10.1177/2040622320976996 10.1007/s00259-020-04815-w 10.1001/jamaoncol.2016.2453 10.1097/RLU.0000000000001758 10.1016/j.chest.2015.10.082 10.1016/j.cpet.2019.08.006 10.2967/jnmt.117.204933 10.1001/jamaoncol.2017.3064 10.1016/j.acra.2016.08.005 10.1259/bjr.20190832 10.1097/RLU.0000000000002692 10.1053/j.ajkd.2019.03.433 10.1186/s40425-019-0820-9 10.1136/jitc-2021-002890corr1 10.4070/kcj.2021.0089 10.2478/raon-2021-0019 10.1001/jamaoncol.2016.1051 10.1001/jamaoncol.2017.2925 10.1080/07357907.2021.1994586 10.1016/j.cllc.2018.08.008 10.1186/s12916-020-01549-2
Clinical & Translational Oncology : Official Publication ... Tatar G, Alçin G et. al.

May 21st, 2022 - Immunotherapy is an effective treatment method for cancer cells with humoral and cellular immune mechanisms of action but triggers an inflammatory response and disrupts standard protective immune tolerance. Early detection of immune-related advers...

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
https://clinicaltrials.gov/ct2/show/NCT03377491

May 20th, 2022 - PAST PRE-CLINICAL AND CLINICAL EXPERIENCE: The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in vitro and in vivo pancreatic adenocarcinoma pre-clinical models both as a single modality treatment and in com...

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Trip...
https://clinicaltrials.gov/ct2/show/NCT02484404

May 20th, 2022 - Background: Disruption of the immune checkpoint PD-1/PD-L1 pathway yielded clinical activity in subsets of advanced solid tumors, such as melanoma and lung cancer. Olaparib (O), a PARP inhibitor (PARPi), has demonstrated single agent activity in r...

see more →

Guidelines  38 results

Clinical features, molecular characteristics and surgical management of primary penile ...
https://doi.org/10.1097/CMR.0000000000000788
Melanoma Research; Cakir OO, Pozzi E et. al.

Nov 30th, 2021 - Penile mucosal melanoma is an aggressive and rare genital malignancy. The aim of the present study was to review the management and outcomes of a homogenous cohort of patients with histologically confirmed penile mucosal melanoma, at a single spec...

New Eye Cancer Therapy Shown to Target Cancer Cells, Spare Vision
https://www.aao.org/newsroom/news-releases/detail/new-eye-cancer-therapy-shown-to-target-cancer-cell
American Academy of Ophthalmology

Nov 15th, 2021 - NEW ORLEANS, La. – Choroidal melanoma is a rare cancer that affects the back of the eye. If the tumor grows, it can cause the retina to detach, leading to vison loss. And if it spreads to other parts of the body, it can be fatal. There are no appr...

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Can...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482100
Current Oncology (Toronto, Ont.); Thawer A, Miller WH et. al.

Oct 1st, 2021 - The combination of dabrafenib and trametinib is a well-established treatment for BRAF-mutated melanoma. However, the effectiveness of this approach may be hindered by the development of treatment-related pyrexia syndrome, which occurs in at least ...

Annual Report to the Nation: Rapid Decrease in Lung Cancer and Melanoma Deaths Lead Overall Continued Decline in Cancer Death Rate
http://pressroom.cancer.org/ARN2021
American Cancer Society

Jul 8th, 2021 - Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death ...

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0018
Journal of the National Comprehensive Cancer Network : JN... Swetter SM, Thompson JA et. al.

Apr 13th, 2021 - Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), ...

see more →

Drugs  50 results see all →

Clinicaltrials.gov  978 results

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03027388

May 20th, 2022 - Background: Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet ne...

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

May 20th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02133196

May 20th, 2022 - Background: Patients with metastatic non-small cell lung cancer (NSCLC) have few approved therapeutic options and those that exist are of transient benefit. Recent clinical experiences with experimental agents that release checkpoints on the host ...

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
https://clinicaltrials.gov/ct2/show/NCT03018288

May 20th, 2022 - Background: Malignant gliomas are unfortunately, in most cases, a uniformly fatal tumor. Despite aggressive surgery, radiation treatment (RT) and chemotherapy at initial diagnosis these tumors almost always recur. Many clinical trials in glioblast...

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
https://clinicaltrials.gov/ct2/show/NCT03830229

May 20th, 2022 - Background: BRCA1-Associated Protein-1 (BAP1), a deubiquitinase involved in regulating DNA repair enzymes, is believed to be a prominent mutation in malignant mesothelioma Germline mutations involving BAP1 have been reported in familial studies. T...

see more →

News  3,507 results

Experts Urge Stopping Melanoma Trial Because of Failure and Harm
https://www.medscape.com/viewarticle/974244

May 19th, 2022 - New results from a phase 3 clinical trial may shut the door on the addition of progressive death–1 or PD–ligand 1 inhibitors to the combination of BRAF and MEK inhibitors for the treatment of BRAF V600–mutated melanoma. The approach seemed promisi...

Study Hints at a Mechanism Behind Aggressive Melanoma
https://www.medscape.com/viewarticle/973804

May 11th, 2022 - A mutation in a gene involved in chromatin remodeling is associated with aggressive melanoma, according to a new study that combined in vitro and animal model data. The gene, ARID2, is a part of the switch/sucrose nonfermentable (SWI/SNF) complex,...

Study hints at a mechanism behind aggressive melanoma
https://www.mdedge.com/hematology-oncology/article/254453/melanoma/study-hints-mechanism-behind-aggressive-melanoma
Jim Kling

May 9th, 2022 - A mutation in a gene involved in chromatin remodeling is associated with aggressive melanoma, according to a new study that combined in vitro and animal model data. The gene, ARID2, is a part of the switch/sucrose nonfermentable (SWI/SNF) complex,.

Substantial Medical Debt, Bankruptcy Linked to Thyroid Cancer
https://www.medscape.com/viewarticle/973618

May 9th, 2022 - Patients with thyroid cancer may experience greater financial challenges compared to those with other common cancers, a recent review suggests. Researchers found, for instance, that patients with thyroid cancer had higher total yearly healthcare e...

Impact of the COVID-19 Pandemic on Characteristics of Cutaneous Tumors Treated by Mohs Micrographic Surgery
https://www.mdedge.com/dermatology/article/254404/melanoma/impact-covid-19-pandemic-characteristics-cutaneous-tumors
Julie A. Croley, MD, Paige Hoyer, MD et. al.

May 6th, 2022 - The COVID-19 pandemic has brought about unprecedented changes and challenges to medical practice, including new public health measure legislation, local and national medical authority recommendations, nursing home and other ancillary health center.

see more →

Patient Education  33 results see all →